We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

27 hedge funds and large institutions have $8.88M invested in Moleculin Biotech in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

336% more capital invested

Capital invested by funds: $2.04M → $8.88M (+$6.84M)

45% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 11

23% more funds holding

Funds holding: 22 → 27 (+5)

0.02% more ownership

Funds ownership: 0% → 0.02% (+0.02%)

Holders
27
Holders Change
+5
Holders Change %
+22.73%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
16
Increased
5
Reduced
–
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Sio Capital Management
New York
+$4.71M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$1.81M
3
BlackRock
BlackRock
New York
+$1.13M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$614K
5
Northern Trust
Northern Trust
Illinois
+$174K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$756K
2
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$105K
3
UBS Group
UBS Group
Switzerland
-$29K
4
HighTower Advisors
HighTower Advisors
Illinois
-$21K
5
LWMG
Levy Wealth Management Group
Pennsylvania
-$11K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Sio Capital Management
New York
$3.93M +$4.71M +2,568 New
Vanguard Group
2
Vanguard Group
Pennsylvania
$1.91M +$1.81M +986 +375%
BlackRock
3
BlackRock
New York
$977K +$1.13M +619 +3,258%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$713K +$614K +335 +256%
Northern Trust
5
Northern Trust
Illinois
$207K +$174K +95 +238%
HIIFS
6
Harel Insurance Investments & Financial Services
Israel
$136K +$49.5K +27 New
SFI
7
Susquehanna Fundamental Investments
Pennsylvania
$129K +$154K +84 New
Truist Financial
8
Truist Financial
North Carolina
$119K – – –
Squarepoint
9
Squarepoint
New York
$118K +$132K +72 +1,440%
TSS
10
Two Sigma Securities
New York
$111K +$134K +73 New
CSS
11
Cubist Systematic Strategies
Connecticut
$109K +$130K +71 New
OQS
12
Occudo Quantitative Strategies
Florida
$90K +$108K +59 New
WIC
13
Whitegate Investment Counselors
New Hampshire
$69K – – –
RJA
14
Raymond James & Associates
Florida
$61K +$73.3K +40 New
Citadel Advisors
15
Citadel Advisors
Florida
$56K +$67.8K +37 New
Charles Schwab
16
Charles Schwab
California
$50K +$58.6K +32 New
Morgan Stanley
17
Morgan Stanley
New York
$39K +$47.6K +26 New
Bank of America
18
Bank of America
North Carolina
$27K – – –
Rockefeller Capital Management
19
Rockefeller Capital Management
New York
$12K +$14.7K +8 New
SPIA
20
Steward Partners Investment Advisory
New York
$4.08K +$5.5K +3 New
Osaic Holdings
21
Osaic Holdings
Arizona
$3K – – –
CFO
22
CVA Family Office
Colorado
$2K +$1.83K +1 New
APA
23
American Portfolios Advisors
New York
$1.36K – – –
CAPTRUST Financial Advisors
24
CAPTRUST Financial Advisors
North Carolina
$1K – – –
PWMG
25
Prestige Wealth Management Group
New Jersey
$1K – – –
1
2

MBRX Hedge Fund Activity: Q1 2021 in Review

27 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q1 2021, worth a combined $8.88M — up 336% from $2.04M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new MBRX positions and 11 closed out — a net gain of 5 holders — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Sio Capital Management, opening a new position worth an estimated $4.71M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $756K sold.

  • 27 institutional investors held Moleculin Biotech (MBRX) as of Q1 2021, up from 22 in Q4 2020.
  • Funds reported $8.88M of Moleculin Biotech stock for Q1 2021, up 336% quarter-over-quarter.
  • 16 funds opened new Moleculin Biotech positions in Q1 2021 and 11 closed out, a net change of +5 holders.
  • The largest Moleculin Biotech buyer in Q1 2021 was Sio Capital Management, an estimated $4.71M added.
  • The largest Moleculin Biotech seller in Q1 2021 was Renaissance Technologies, an estimated $756K sold.

Based on aggregated 13F filings for Q1 2021.